» Articles » PMID: 29925522

Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases

Overview
Journal Pharmacol Rev
Specialty Pharmacology
Date 2018 Jun 22
PMID 29925522
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Platelets are essential for clotting in the blood and maintenance of normal hemostasis. Under pathologic conditions such as atherosclerosis, vascular injury often results in hyperactive platelet activation, resulting in occlusive thrombus formation, myocardial infarction, and stroke. Recent work in the field has elucidated a number of platelet functions unique from that of maintaining hemostasis, including regulation of tumor growth and metastasis, inflammation, infection, and immune response. Traditional therapeutic targets for inhibiting platelet activation have primarily been limited to cyclooxygenase-1, integrin , and the P2Y receptor. Recently identified signaling pathways regulating platelet function have made it possible to develop novel approaches for pharmacological intervention in the blood to limit platelet reactivity. In this review, we cover the newly discovered roles for platelets as well as their role in hemostasis and thrombosis. These new roles for platelets lend importance to the development of new therapies targeted to the platelet. Additionally, we highlight the promising receptor and enzymatic targets that may further decrease platelet activation and help to address the myriad of pathologic conditions now known to involve platelets without significant effects on hemostasis.

Citing Articles

Metagenomic Insights into Microbial Signatures in Thrombi from Acute Ischemic Stroke Patients Undergoing Endovascular Treatment.

Thirupathi K, Ghozy S, Reda A, Ranatunga W, Ruben M, Armin Z Brain Sci. 2025; 15(2).

PMID: 40002490 PMC: 11853128. DOI: 10.3390/brainsci15020157.


Association between air pollutants and blood cell counts in pediatric patients with asthma: a retrospective observational study.

Huang K, Pan H, Hsieh T, Chen C, Cheng F BMC Public Health. 2025; 25(1):306.

PMID: 39856641 PMC: 11760106. DOI: 10.1186/s12889-025-21517-w.


From Blood to Therapy: The Revolutionary Application of Platelets in Cancer-Targeted Drug Delivery.

Xie L, Gan F, Hu Y, Zheng Y, Lan J, Liu Y J Funct Biomater. 2025; 16(1).

PMID: 39852571 PMC: 11766108. DOI: 10.3390/jfb16010015.


Platelet signaling in immune landscape: comprehensive mechanism and clinical therapy.

Yan M, Wang Z, Qiu Z, Cui Y, Xiang Q Biomark Res. 2024; 12(1):164.

PMID: 39736771 PMC: 11686937. DOI: 10.1186/s40364-024-00700-y.


Platelet-enriched microRNAs as novel biomarkers in atherosclerotic and cardiovascular disease patients.

Masoudikabir P, Shirazy M, Taghizadeh F, Gheydari M, Hamidpour M ARYA Atheroscler. 2024; 20(4):47-67.

PMID: 39717424 PMC: 11663285. DOI: 10.48305/arya.2024.41664.2898.


References
1.
James S, Akerblom A, Cannon C, Emanuelsson H, Husted S, Katus H . Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2009; 157(4):599-605. DOI: 10.1016/j.ahj.2009.01.003. View

2.
Lyman G, Khorana A . Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol. 2009; 27(29):4821-6. PMC: 2764390. DOI: 10.1200/JCO.2009.22.3032. View

3.
Faxon D, Creager M, Smith Jr S, Pasternak R, Olin J, Bettmann M . Atherosclerotic Vascular Disease Conference: Executive summary: Atherosclerotic Vascular Disease Conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation. 2004; 109(21):2595-604. DOI: 10.1161/01.CIR.0000128517.52533.DB. View

4.
Capodanno D, Ferreiro J, Angiolillo D . Antiplatelet therapy: new pharmacological agents and changing paradigms. J Thromb Haemost. 2013; 11 Suppl 1:316-29. DOI: 10.1111/jth.12219. View

5.
Manly D, Wang J, Glover S, Kasthuri R, Liebman H, Key N . Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism. Thromb Res. 2009; 125(6):511-2. PMC: 2878897. DOI: 10.1016/j.thromres.2009.09.019. View